Inborn errors of metabolism and coronavirus disease 2019: Evaluation of the metabolic outcome.
COVID-19
SARS-CoV-2
metabolic decompensation
metabolic disorders
prognosis
Journal
Pediatrics international : official journal of the Japan Pediatric Society
ISSN: 1442-200X
Titre abrégé: Pediatr Int
Pays: Australia
ID NLM: 100886002
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
revised:
09
07
2021
received:
28
05
2021
accepted:
27
07
2021
pubmed:
31
7
2021
medline:
13
4
2022
entrez:
30
7
2021
Statut:
ppublish
Résumé
Infectious diseases can result in a catabolic state and possibly trigger an acute metabolic decompensation in inborn errors of metabolism (IEM), which could be life threatening. Studies regarding the course of severe acute respiratory syndrome coronavirus 2 infections in patients with IEM are generally limited to case reports. Here, we aimed to evaluate the clinical findings of coronavirus disease 2019 (COVID-19) and describe the impact of severe acute respiratory syndrome coronavirus 2 infections on metabolic outcomes in IEM patients. Patients who were diagnosed with different types of IEM and developed microbiologically confirmed COVID-19 infection were included. Clinical findings and laboratory results were recorded retrospectively in terms of both IEM and COVID-19. Eleven patients with diagnosis of intoxication type metabolic disorders, five patients with energy metabolism disorders, and six patients with complex molecular disorders were enrolled. The most frequent clinical finding was fever (52.1%) followed by fatigue/myalgia (47.8%). None of the patients was younger than 1 year. None of the patients presented severe or critical disease. In terms of metabolic decompensation, two patients diagnosed with propionic acidemia, one patient with methylmalonic acidemia and one patient with 3-hydroxy-3-methylglutaryl-CoA lyase deficiency presented clinical and biochemical findings of an acute metabolic attack. Based on our results, IEM are not found to be an additional risk factor for severe COVID-19 infection. However, patients with intoxication type and energy metabolism disorders should be considered as a vulnerable population for COVID-19 and have a major risk of developing acute metabolic decompensation that can lead to life-threatening complications.
Sections du résumé
BACKGROUND
BACKGROUND
Infectious diseases can result in a catabolic state and possibly trigger an acute metabolic decompensation in inborn errors of metabolism (IEM), which could be life threatening. Studies regarding the course of severe acute respiratory syndrome coronavirus 2 infections in patients with IEM are generally limited to case reports. Here, we aimed to evaluate the clinical findings of coronavirus disease 2019 (COVID-19) and describe the impact of severe acute respiratory syndrome coronavirus 2 infections on metabolic outcomes in IEM patients.
METHODS
METHODS
Patients who were diagnosed with different types of IEM and developed microbiologically confirmed COVID-19 infection were included. Clinical findings and laboratory results were recorded retrospectively in terms of both IEM and COVID-19.
RESULTS
RESULTS
Eleven patients with diagnosis of intoxication type metabolic disorders, five patients with energy metabolism disorders, and six patients with complex molecular disorders were enrolled. The most frequent clinical finding was fever (52.1%) followed by fatigue/myalgia (47.8%). None of the patients was younger than 1 year. None of the patients presented severe or critical disease. In terms of metabolic decompensation, two patients diagnosed with propionic acidemia, one patient with methylmalonic acidemia and one patient with 3-hydroxy-3-methylglutaryl-CoA lyase deficiency presented clinical and biochemical findings of an acute metabolic attack.
CONCLUSIONS
CONCLUSIONS
Based on our results, IEM are not found to be an additional risk factor for severe COVID-19 infection. However, patients with intoxication type and energy metabolism disorders should be considered as a vulnerable population for COVID-19 and have a major risk of developing acute metabolic decompensation that can lead to life-threatening complications.
Identifiants
pubmed: 34329521
doi: 10.1111/ped.14938
pmc: PMC8447071
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14938Informations de copyright
© 2021 Japan Pediatric Society.
Références
Saudubray JM, Cazorla AG. Clinical approach to inborn errors of metabolism in pediatrics. In: Saudubray JM, Baumgartner MR, Walter J (eds). Inborn Metabolic Diseases Diagnosis and Treatment, 6th edn. Springer-Verlag, Heidelberg, 2016; 4-69.
World Health Organization. Homepage on the internet. Avaliable at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Accessed April 21, 2021.
Dong Y, Mo X, Hu Y et al. Epidemiology of COVID-19 among children in China. Pediatrics 2020; 145: e20200702.
Çokuğraş H, Önal P. SARS-CoV-2 infection in children. Turk. Pediatri. Ars. 2020; 55: 95-102.
Cura-Yayla BC, Özsürekçi Y, Aykaç K et al. Characteristics and management of children with COVID-19 in Turkey. Balkan Med. J. 2020; 37: 341-7.
Haslak F, Yıldız M, Adrovic A, Şahin S, Barut K, Kasapçopur Ö. A recently explored aspect of the iceberg named COVID-19:multisystem inflammatory syndrome in children (MIS-C). Turk. Arch. Pediatr. 2021; 56: 3-9.
CDC Health Alert Network. Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with Coronavirus Disease 2019 (COVID-19). https://emergency.cdc.gov/han/2020/han00432.asp. Accessed November 16, 2020.
Mistry P, Balwani M, Barbouth D et al. Gaucher disease and SARS-CoV-2 infection: Emerging management challenges. Mol. Genet. Metab. 2020; 130(3): 164-9.
Fiumara A, Lanzafame G, Arena A et al. COVID-19 pandemic outbreak and its psychological impact on patients with rare lysosomal diseases. J. Clin. Med. 2020; 9: 2716.
Fierro L, Nesheiwat N, Naik H, Narayanan P, Mistry PK, Balwani M. Gaucher disease and SARS-CoV-2 infection: Experience from 181 patients in New York. Mol. Genet. Metab. 2021; 132: 44-8.
Elmonem MA, Belanger-Quintana A, Bordugo A et al. The impact of COVID-19 pandemic on the diagnosis and management of inborn errors of metabolism: A global perspective. Mol. Genet. Metab. 2020; 131: 285-8.
Oge-Enver E, Hopurcuoglu D, Ahmadzada S, Zubarioglu T, Aktuglu-Zeybek AC, Kiykim E. Challenges of following patients with inherited metabolic diseases during the COVID-19 outbreak. A cross-sectional online survey study. J. Pediatr. Endocrinol. Metab. 2020; 34(1): 103-7.
Zubarioglu T, Hopurcuoglu D, Uygur E et al. The impact of telemedicine for monitoring and treatment of phenylketonuria patients on metabolic outcome during coronavirus disease-19 outbreak. Telemed. J. e Health 2021. https://doi.org/10.1089/tmj.2020.0569
Wongkittichote P, Watson JR, Leonard JM, Toolan ER, Dickson PI, Grange DK. Fatal COVID-19 infection in a patient with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency: A case report. JIMD Rep. 2020; 56: 40-5.
Caciotti A, Procopio E, Pochiero F et al. SARS-CoV-2 infection in a patient with propionic acidemia. Orphanet J. Rare Dis. 2020; 15: 306.
Parri N, Lenge M, Buonsenso D, Coronavirus Infection in Pediatric Emergency Departments (CONFIDENCE) Research Group. Children with Covid-19 in pediatric emergency departments in Italy. N. Engl. J. Med. 2020; 383(2): 187-90.
Önal P, Kılınç AA, Aygün F, Durak C, Çokuğraş H. COVID-19 in Turkey: A tertiary center experience. Pediatr Int 2020; 63: 797-805. https://doi.org/10.1111/ped.14549
Shekerdemian LS, Mahmood NR, Wolfe KK et al. Characteristics and outcomes of children with Coronavirus disease 2019 (COVID-19) infection admitted to US and Canadian Pediatric Intensive Care Units. JAMA Pediatr. 2020; 174: 868-73.
Panigrahy N, Policarpio J, Ramanathan R. Multisystem inflammatory syndrome in children and SARS-CoV-2: A scoping review. J. Pediatr. Rehabil. Med. 2020; 13: 301-16.
Prietsch V, Lindner M, Zschocke J, Nyhan WL, Hoffmann GF. Emergency management of inherited metabolic diseases. J. Inherit. Metab. Dis. 2002; 25: 531-46.